Is Interleukin-1 Receptor Blockade Ready for Prime Time in Patients With Severe Sepsis and Macrophage Activation Syndrome?

Crit Care Med. 2016 Feb;44(2):443-4. doi: 10.1097/CCM.0000000000001460.

Authors

Daniel W Johnson¹, Andre C Kalil

Affiliation

¹ Division of Critical Care, Department of Anesthesiology, University of Nebraska Medical Center, Omaha, NE Division of Infectious Diseases, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE.

PMID: 26771789
DOI: 10.1097/CCM.0000000000001460

No abstract available

Publication types

Editorial
Comment

MeSH terms

Disseminated Intravascular Coagulation / epidemiology*
Female
Humans
Interleukin 1 Receptor Antagonist Protein / therapeutic use*
Macrophage Activation Syndrome / epidemiology*
Male
Receptors, Interleukin-1 / antagonists & inhibitors*
Sepsis / drug therapy*
Sepsis / epidemiology*

Substances

Interleukin 1 Receptor Antagonist Protein
Receptors, Interleukin-1